Funding The author(s) declared that financial support was not received for this work and/or its publication
After 26 weeks of follow-up, the two higher drug doses elicited a mean 12.1% weight reduction from baseline, whereas those on placebo lost 2.3% of their body weight
Phase 2 trial data published in 2023 in the New England Journal of Medicine (Jastreboff et al., NEJM 2023) reported mean weight reductions of up to approximately 24% over 48 weeks in adults with obesity notably higher than results seen with currently approved agents
This means discontinuing Retatrutide after reaching goal weight typically leads to weight regain
As the discontinuation rates were also high with the twice daily danuglipron at the phase 2 obesity trial (as discussed above), twice daily danuglirpon formulation will not advance into phase 3 studies, but an improved once-daily formulation with an aim to improve tolerability profile is currently under assessment [27]
Nutrafol HGNs are expected to perform as intended when used alongside GLP-1 therapies, and GLP-1 medications are not expected to impact the function of Nutrafols ingredients
